An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.

Autor: Snell D; Numab Therapeutics AG, Horgen, Switzerland., Gunde T; Numab Therapeutics AG, Horgen, Switzerland., Warmuth S; Numab Therapeutics AG, Horgen, Switzerland., Chatterjee B; Numab Therapeutics AG, Horgen, Switzerland., Brock M; Numab Therapeutics AG, Horgen, Switzerland., Hess C; Numab Therapeutics AG, Horgen, Switzerland., Johansson M; Numab Therapeutics AG, Horgen, Switzerland., Simonin A; Numab Therapeutics AG, Horgen, Switzerland., Spiga FM; Numab Therapeutics AG, Horgen, Switzerland., Weinert C; Numab Therapeutics AG, Horgen, Switzerland., Kirk N; Numab Therapeutics AG, Horgen, Switzerland., Bassler N; Numab Therapeutics AG, Horgen, Switzerland., Campos Carrascosa L; Numab Therapeutics AG, Horgen, Switzerland., Flückiger N; Numab Therapeutics AG, Horgen, Switzerland., Heiz R; Numab Therapeutics AG, Horgen, Switzerland., Wagen S; Numab Therapeutics AG, Horgen, Switzerland., Giezendanner N; Numab Therapeutics AG, Horgen, Switzerland., Alberti A; Numab Therapeutics AG, Horgen, Switzerland., Yaman Y; Numab Therapeutics AG, Horgen, Switzerland., Mahler D; Numab Therapeutics AG, Horgen, Switzerland., Diem D; Numab Therapeutics AG, Horgen, Switzerland., Lichtlen P; Numab Therapeutics AG, Horgen, Switzerland., Urech D; Numab Therapeutics AG, Horgen, Switzerland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2023 Jul 12; Vol. 12 (1), pp. 2233401. Date of Electronic Publication: 2023 Jul 12 (Print Publication: 2023).

Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

Autor: Warmuth S; Numab Therapeutics AG, Waedenswil, Switzerland., Gunde T; Numab Therapeutics AG, Waedenswil, Switzerland., Snell D; Numab Therapeutics AG, Waedenswil, Switzerland., Brock M; Numab Therapeutics AG, Waedenswil, Switzerland., Weinert C; Numab Therapeutics AG, Waedenswil, Switzerland., Simonin A; Numab Therapeutics AG, Waedenswil, Switzerland., Hess C; Numab Therapeutics AG, Waedenswil, Switzerland., Tietz J; Numab Therapeutics AG, Waedenswil, Switzerland., Johansson M; Numab Therapeutics AG, Waedenswil, Switzerland., Spiga FM; Numab Therapeutics AG, Waedenswil, Switzerland., Heiz R; Numab Therapeutics AG, Waedenswil, Switzerland., Flückiger N; Numab Therapeutics AG, Waedenswil, Switzerland., Wagen S; Numab Therapeutics AG, Waedenswil, Switzerland., Zeberer J; Numab Therapeutics AG, Waedenswil, Switzerland., Diem D; Numab Therapeutics AG, Waedenswil, Switzerland., Mahler D; Numab Therapeutics AG, Waedenswil, Switzerland., Wickihalder B; Numab Therapeutics AG, Waedenswil, Switzerland., Muntwiler S; Numab Therapeutics AG, Waedenswil, Switzerland., Chatterjee B; Numab Therapeutics AG, Waedenswil, Switzerland., Küttner B; Numab Therapeutics AG, Waedenswil, Switzerland., Bommer B; Numab Therapeutics AG, Waedenswil, Switzerland., Yaman Y; Numab Therapeutics AG, Waedenswil, Switzerland., Lichtlen P; Numab Therapeutics AG, Waedenswil, Switzerland., Urech D; Numab Therapeutics AG, Waedenswil, Switzerland.

Publikováno v: Oncoimmunology [Oncoimmunology] 2021 Dec 02; Vol. 10 (1), pp. 2004661. Date of Electronic Publication: 2021 Dec 02 (Print Publication: 2021).

Selection of Structure-Switching DNA Aptamers Binding Soluble Small Molecules and SPR Validation of Enrichment.

Autor: Tenaglia E; Institute of Bioengineering, Ecole Polytechnique Fédérale De Lausanne (EPFL), Lausanne, Vaud, Switzerland., Spiga FM; Institute of Bioengineering, Ecole Polytechnique Fédérale De Lausanne (EPFL), Lausanne, Vaud, Switzerland., Guiducci C; Institute of Bioengineering, Ecole Polytechnique Fédérale De Lausanne (EPFL), Lausanne, Vaud, Switzerland. carlotta.guiducci@epfl.ch.

Publikováno v: Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2018; Vol. 1811, pp. 183-197.

Label-free detection of tobramycin in serum by transmission-localized surface plasmon resonance.

Autor: Cappi G; †Institute of Bioengineering, École polytechnique fédérale de Lausanne, Lausanne, CH-1015 Switzerland., Spiga FM; †Institute of Bioengineering, École polytechnique fédérale de Lausanne, Lausanne, CH-1015 Switzerland., Moncada Y; ‡Bio-Lab, STMicroelectronics, Agrate Brianza, Monza and Brianza, 20864, Italy., Ferretti A; †Institute of Bioengineering, École polytechnique fédérale de Lausanne, Lausanne, CH-1015 Switzerland., Beyeler M; †Institute of Bioengineering, École polytechnique fédérale de Lausanne, Lausanne, CH-1015 Switzerland., Bianchessi M; ‡Bio-Lab, STMicroelectronics, Agrate Brianza, Monza and Brianza, 20864, Italy., Decosterd L; §Laboratory and Division of Clinical Pharmacology, Lausanne University Hospital (CHUV), Lausanne, CH-1011 Switzerland., Buclin T; §Laboratory and Division of Clinical Pharmacology, Lausanne University Hospital (CHUV), Lausanne, CH-1011 Switzerland., Guiducci C; †Institute of Bioengineering, École polytechnique fédérale de Lausanne, Lausanne, CH-1015 Switzerland.

Publikováno v: Analytical chemistry [Anal Chem] 2015 May 19; Vol. 87 (10), pp. 5278-85. Date of Electronic Publication: 2015 Apr 28.

Hybridization chain reaction performed on a metal surface as a means of signal amplification in SPR and electrochemical biosensors.

Autor: Spiga FM; Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Bonyár A; Department of Electronics Technology at the Budapest University of Technology and Economics, Budapest, Hungary., Ring B; Department of Electronics Technology at the Budapest University of Technology and Economics, Budapest, Hungary., Onofri M; Interdepartmental Center for Industrial Research on Health Sciences & Technologies, University of Bologna, Via Irnerio 48, Bologna 40126, Italy., Vinelli A; Department of Pharmacy and Biotechnologies at the University of Bologna, Via Irnerio 48, Bologna 40126, Italy., Sántha H; Department of Electronics Technology at the Budapest University of Technology and Economics, Budapest, Hungary., Guiducci C; Institute of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland., Zuccheri G; Interdepartmental Center for Industrial Research on Health Sciences & Technologies, University of Bologna, Via Irnerio 48, Bologna 40126, Italy; Department of Pharmacy and Biotechnologies at the University of Bologna, Via Irnerio 48, Bologna 40126, Italy; Istituto Nanoscienze of the National Research Council, S3 Laboratory, Italy. Electronic address: giampaolo.zuccheri@unibo.it.

Publikováno v: Biosensors & bioelectronics [Biosens Bioelectron] 2014 Apr 15; Vol. 54, pp. 102-8. Date of Electronic Publication: 2013 Oct 31.